To support generic drug companies in obtaining a market license for their orally inhaled drug products (OIDPs), Nanopharm and FLUIDDA entered into an exclusive collaboration to combine Nanopharm’s SmartTrack™ with FLUIDDA’s Functional Respiratory Imaging technology to create a unique in-vitro in-silico platform. This allows pharma companies to shorten their clinical pathways – and potentially avoid comparative clinical endpoint studies by demonstrating a holistic understanding of both the product and patient-specific variables associated with the performance of their drug product, without having to go into the clinic.
In this interview at the ERS convention in Barcelona, Gemma Budd, Director Business Development of Nanopharm, an Aptar Company, and Dr Jan De Backer, CEO of Fluidda, explains the context behind the industry and regulatory need and what the technologies offer in response.
Click here to see the short video on LinkedIn
Related Posts
FDA’s Evolving Stance on In-Silico Studies in Bioequivalence Testing
The paper titled “Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques” explores the use of advanced analytical methods to improve our understanding of the performance of dry powder inhalers (DPIs).
Nanopharm Newsletter November 2024
Nanopharm is leading innovation in OINDP, inhalation, and nasal drug delivery with FDA collaboration and advanced spray-drying technology.
Interview with Jane Provis Evans, Head cGMP services at Nanopharm
In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.
